What Should Doctors Know About FDA’s Black Box Change for Hormone Replacement Therapy Drugs? - Takeaways - MDSpire

What Should Doctors Know About FDA’s Black Box Change for Hormone Replacement Therapy Drugs?

A Keck Medicine of USC breast surgeon discusses the FDA’s decision — and whether using HRT to treat menopause symptoms actually affects breast cancer risk.

  • By

  • January 28, 2026

  • 8 min

Share

  • 1

    The FDA removed the black box warning on hormone replacement therapy (HRT) drugs, which may encourage more women to consider HRT for menopause symptoms.

  • 2

    The previous warning linked HRT to increased risks of breast cancer and other health issues, discouraging both patients and physicians from its use.

  • 3

    Recent research indicates that HRT may not increase cancer mortality and could even decrease mortality risk for women starting HRT before age 60.

  • 4

    Doctors should assess individual risks and benefits of HRT, as not all menopause-like symptoms are caused by menopause itself.

  • 5

    Women with a history of hormone-sensitive breast cancer should avoid HRT, while those with triple-negative breast cancer may benefit from it.

Original Source(s)

What Should Doctors Know About FDA’s Black Box Change for Hormone Replacement Therapy Drugs?

  • by

  • January 28, 2026

Related Content

A New Era in Alzheimer’s Care: The Shift Toward Early Detection and Prevention

The future of Alzheimer’s care holds incredible promise. Recently, leaders from medicine, government, and the pharmaceutical industry gathered to discuss this exact topic.

  • by

  • March 13, 2026

  • 8 min
A Narrative Review: Do Systemic Drugs Used in the Treatment of Psoriatic Disease Affect Alzheimer’s Disease?

Combination Therapy Shows Potential in Psoriasis, Obesity

Researchers assess whether adding tirzepatide to ixekizumab affects skin and weight outcomes in adults with moderate to severe plaque psoriasis.